Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden.

2024年8月16日 · Purpose: Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD.

2024年5月2日 · Primary endpoint was treatment success (TS) at 6 months defined as patient being alive, achieving PR or CR of cGVHD, having no relapse of underlying disease and requiring no secondary treatment...

2019年3月14日 · Since that publication, 2 major advances have occurred: first, outcome studies have shown that <20% of patients with cGVHD achieve a durable partial (PR) or complete response (CR) and survive 1 year after initial therapy without additional systemic therapy, 11 indicating that treatment-refractory cGVHD is relatively common 12 and patients ...

6 天之前 · Eighty-two percent of patients had severe cGVHD with a median of three organs involved. ... including 14.7% complete remission (CR) and 42.6% partial response (PR). The ORR at three and six months ...

For cGVHD, a partial response (PR) was defined as a change from extensive to limited stage or a higher than 50% improvement in objective parameters of cGVHD manifestations, such as surface area involvement of skin and transaminase or bilirubin level. A response in oral cGVHD required symptomatic improvement and physician assessment.

北京大学人民医院应用小剂量MTX方案作为cGVHD的一线治疗和难治性cGVHD的挽救治疗，用量5~10 mg/m 2 第1、3（或4）、8天给药，此后每周1次，直至GVHD症状缓解或不良反应不能耐受；如果患者白细胞计数低于2×10 9 /L、血小板计数低于50×10 9 /L，可减至5 mg/m 2 。

2024年7月31日 · Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic hematopoietic cell transplant. The development of cGVHD involves a complex,...

2024年12月1日 · Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT).

2024年1月1日 · Most GvHD trials are focused on the ORR and partial response rates (PRR). The evidence for optimal agents for each organ is limited, and therefore, our study results are striking for differences in organ-ORR yields for a clinically meaningful difference.